ICU Medical beats, expands margins, reiterates guidance despite macro cost headwinds

 

ICU Medical beats Q1 estimates with non-GAAP EPS $1.97 (+15% YoY), expands margins and reiterates full-year guidance despite macro cost headwinds

• Consensus Q1 2026 EPS was $1.78, below reported non-GAAP EPS of $1.97, indicating an earnings beat.
• Q1 revenue $526M, +1% organic but -12% reported from IV Solutions JV deconsolidation.
• Adjusted EPS $1.97, up 15% YoY, with adjusted EBITDA flat at $99M amid tariff headwinds.
• Adjusted gross margin reached 41%, ahead of expectations, helped by mix shift to higher-margin businesses.
• Q1 2026 revenue of $520.6M compared with analyst forecast of $519.9M, a modest outperformance.
• Reported GAAP EPS of $1.20 for the first quarter 2026.
• Consumables grew 2% organic (5% reported); IV Systems grew 6% organic (8% reported, record pumps).
• Vital Care declined 14% organic (59% reported); management targeting flat to slightly down in the near term.
• Full-year revenue, EBITDA and EPS guidance reiterated; roughly $10M higher logistics costs largely offset elsewhere.
• Tariff expense was $10M in Q1 (~2% of revenue); 2026 outlook $40–50M unchanged but mix improves.
• FDA cleared new LifeShield software; Medfusion and CADD hardware clearances delayed by extra testing, not core design.
• Free cash flow was $28M in Q1; company targets improved 2026 FCF to near $150M and <2x leverage.
• Management tone confident; expects core segments to hit record 2026 revenue and further margin expansion from efficiencies.
• Main concern: macro and trade cost volatility and regulatory delays could affect pump and margin upside timing beyond 2026.
• Strong quarter, driven by core segment growth and mix-driven margin expansion offsetting macro and tariff pressures.

https://finviz.com/quote?t=ICUI&p=d